Ongoing studies on KL1’s mechanism, along with medicinal chemistry optimization and in vivo testing in combination with diverse antibiotics against multiple pathogens, will be critical to determine the full therapeutic potential of this host-directed adjuvant in eradicating deep-seated infections. The gene discussed is KITLG; the disease is infection.